Last mentioned: Feb 26, 2026
GSS Strategic Review
Board outlines steps to address unsustainable cash burn levels.
H1 FY26 Earnings Release
Genetic Signatures and ClearView Wealth report half-year results.
Zurich Acquisition Announced
ClearView Wealth enters Scheme Implementation Deed with Zurich.
Genetic Signatures (ASX:GSS) reported a modest revenue increase for H1 FY26 but warned that its current cash burn rate is unsustainable, prompting immediate board intervention. Meanwhile, the broader ASX landscape saw significant consolidation as ClearView Wealth (ASX:CVW) entered a definitive acquisition agreement with Zurich following a period of strong profitability.
This page surfaces every story mentioning Caroline Waldron across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Caroline Waldron was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |